2025 Q4 -tulosraportti
79 päivää sitten
‧46 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 032 | - | - | ||
| 4 147 | - | - | ||
| 2 402 | - | - | ||
| 7 457 | - | - | ||
| 6 533 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenHealthCap - tactical capital strategy Investor Analysis: HealthCap VI and shareholder behavior in Oncopeptides Oncopeptides is in a transition phase where the company is still financed as a development/turnaround case, but at the same time has a commercial product that is starting to generate more structural cash flow expectations. In this situation, the actions of the main shareholders in the 2026 issue become particularly important, especially HealthCap VI and HealthCap VIII. ⸻ 1. HealthCap VI: limited visible issue participation Public information shows that: * HealthCap VIII had clear subscription commitments in the issue. * HealthCap VI is not mentioned as an active issue-supporting party. If HealthCap VI had participated fully pro rata, they could have increased their holding by approximately 7.7 million shares, which would have raised their position to just over 23 million shares. This is not visible in available information. This leads to possible interpretations: Possible scenarios * They completely refrained from subscribing. * They chose not to use the issue as a tool and instead potentially buy shares on the market later. ⸻ 2. Possible tactical capital strategy In small and medium-sized biotech companies, it is not uncommon for larger shareholders to: 1. Participate limitedly in issues when the price is not perceived as optimal. 2. Await important catalysts (e.g., Q1/Q2 reports). 3. Increase exposure in the secondary market if developments confirm the case. This can provide several advantages: * better entry price than the issue price, * greater flexibility in positioning, * opportunity to act after new information rather than before. Since the liquidity in the stock is relatively low, even moderate purchases from institutions can have a significant price impact. ⸻ 3. The flagging pattern: active but selective ownership This is important because it signals that: * the ownership base is still active, * and that the stock is used in more dynamic positioning strategies (not passive long-term ownership). Typical drivers behind such flagging patterns are: * arbitrage linked to issues, * positioning before reports, * market making and liquidity management, * or gradual re-accumulation after capital events. ⸻ 4. Why this is logical in Oncopeptides The company is in an unusual hybrid situation: Operationally: * Product exists and is commercialized. * Sales are growing but are not yet fully stable. Financially: * Cash flow is still negative. * The capital market remains central for financing. Market-wise: * Expectations are divided: between turnaround and continued risk financing. This means that larger shareholders can choose to: * not overexpose themselves in issues, * but instead await commercial confirmation before increasing their stake. ⸻ 5. What the market still discounts That the stock trades below the issue price indicates that the market is still concerned about: * sustainable sales growth, * cash flow profile and burn rate, * potential future capital needs, * and commercial scalability. In practice, the company is still valued more as: a financing case than a stable specialty pharma company. ⸻ 6. Overall interpretation of shareholder behavior HealthCap VI's position can be interpreted in two ways: A. Cautious/neutral interpretation * Capital discipline. * Waiting for a better risk/return profile. * Selective participation in issues. B. Tactical/bullish interpretation * Awaits Q1/Q2 to reduce uncertainty. * Buys later on the market at a weak price. * Optimizes average price rather than locking up capital in an issue. The flagging pattern supports that: * the owners are not abandoning the case, * but rather repositioning themselves. ⸻ 7. Important future signals Bullish signals: 🔥 * increasing net ownership from institutions after reports, * improved sales trend, * reduced cash burn, * partnerships (e.g., Japan), * reduced reliance on issues. Bearish signals: 💀 * continued weak price despite operational improvement, * further capital raising within 12–18 months, * lack of growth acceleration, * decreased institutional interest.·4 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.- ·9 t sittenInvestor Analysis: Oncopeptides – from 6 billion in financing to a market capitalization of 500 Mkr Executive summary Oncopeptides is a clear example of the biotech sector's extreme asymmetry. The company has historically raised approximately: * ~6 billion SEK in capital, but is valued today at approximately: * ~0.5 billion SEK. This means that the market has practically re-evaluated: * the probability of commercial success, * the pipeline value, * and the future cash flow potential very sharply downwards. At the same time, the annual report and regulatory development show that the company is not only trying to commercialize: Pepaxti, but also restructuring its intellectual assets through: Oncopeptides Innovation AB and building further on the PDC platform, including within glioblastoma. This makes the investment case unusually binary: the market today primarily prices in survival and financing risk, while the optionality in the platform largely appears to be discounted away.·4 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·11 t sittenSummary analysis of Oncopeptides Innovation AB and the capital contribution 1. What actually happened In the parent company's note for shares in subsidiaries, a significant increase is visible: * Book value ("carrying amount") for Oncopeptides Innovation AB: * from approximately 25 tkr * to approximately 10,325 tkr * At the same time, it is reported: * Purchases: 10,300 tkr In practice, this means that the parent company has made a capital contribution of approximately 10.3 MSEK to the subsidiary. It is not a matter of: * sales, * operating profit, * or value increase from operations, but an internal financial investment within the group. ⸻ 2. What "Purchases" means here In this type of note, "Purchases" normally means: * shareholder contribution, * new share issue in subsidiary, * or other capitalization. So, it is not about the purchase of goods or operating expenses. The flow is typically: 1. The parent company sends capital to the subsidiary 2. The subsidiary receives: * more cash * higher equity 3. The parent company increases the item: * "shares in subsidiaries" That is why the carrying amount increases so sharply. ⸻ 3. Why Oncopeptides Innovation AB is central Several factors make Oncopeptides Innovation AB appear as the clear recipient: * Started relatively recently * Had very low initial share capital (~25 tkr) * Has: * no employees, * no normal sales, * limited operational activity * At the same time, the company receives a large capital contribution This is a classic pattern for an: * R&D company, * IP company, * or strategic project company within biotech. ⸻ 4. Strategic interpretation The capital contribution does not appear to be administrative or random. It likely signals that Oncopeptides uses Innovation AB as: Möjliga syften (Possible purposes) A. Separate new pipeline or IP Common in biotech: * patents, * preclinical projects, * new technologies are placed in separate companies. Advantages: * risk isolation, * easier partnering, * easier sale, * separate valuation. ⸻ B. Prepare for future license or M&A deals A separate project company makes it easier to: * sell a project, * bring in external investors, * or make collaboration agreements. This is often how larger pharmaceutical companies acquire early technology: * not the entire parent company, * but specific projects or subsidiaries. ⸻ C. Build the next generation pipeline Oncopeptides already has a commercial product: * Pepaxti But the market also knows that the company needs: * new projects, * new pipeline, * future growth. Innovation AB therefore appears to function as: a "container" for future research and development projects. ⸻ 5. Link to pipeline and future projects The analysis points specifically to early projects within: * PDC technology, * new cancer indications, * or preclinical research. A likely example is: * glioblastoma-/GLIOPEP-related projects, * or other early research platforms. The amount (~10 MSEK) is well suited for: * early research, * proof-of-concept, * preclinical development. However, it is too small for larger clinical programs. ⸻ 6. Investor perspective – what the market might miss The most interesting thing is not the sum itself, but the structure. The market tends to focus on: * sales, * quarterly results, * cash flow. But in biotech, the greatest future value is often created: * long before revenues exist. This functions as an option 10.3 MSEK should therefore not primarily be seen as: * a cost, but as: * an investment in future optionality. The outcome is asymmetrical: * the project can become worthless, * or develop into a significant license or acquisition deal. ⸻ 7. Overall assessment Positive signals * The company invests in future pipeline * The structure is strategically well-thought-out * Capital allocation is relatively limited and controlled * Enables future partnering/M&A Risks * No clinical evidence yet * No revenues from the project * Early research phase implies high uncertainty * Future capital needs can lead to dilution ⸻ Conclusion The capital contribution to Oncopeptides Innovation AB is likely a conscious strategic step to build or separate future research projects within the group. It is therefore not just about accounting, but about: * structuring of pipeline, * creation of future business units, * and potential long-term optionality. From an investor's point of view, this is: * potentially an important signal about how Oncopeptides is trying to create the next phase of the company's value development.·3 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·1 päivä sittenOBV trend 📈 The On-Balance Volume (OBV) indicator typically moves in sync with a stock's price, reflecting the balance between buying and selling pressure. This divergence suggests that the recent price weakness has not been driven by higher selling volumes. OBV often acts as an early indicator when investors begin to accumulate long-term positions well before a revaluation.
- ·2 päivää sittenThe situation and going forward In biotech companies, it is often observed that the share price continues to trade weakly during the subscription period itself, especially when the issue is made with such a large discount as in this case, approximately 34 percent against TERP. One reason is that guarantee consortia and arbitrage trading can create additional selling pressure in the share. At the same time, the market usually interprets the situation as the company having now secured its financing, but that it needed to offer very attractive terms to successfully raise the capital. A discount of 34 % is quite aggressive but not uncommon in smaller biotech companies with high risk. This usually signals that the company has prioritized securing capital quickly over protecting the share price level. How the share develops after the issue is often determined by several factors. Investors look closely at how much has been subscribed by existing owners compared to guarantors, and how long the new capital is expected to last. When larger owners and management participate heavily in the issue, it is usually seen as a sign of strength, while it is often perceived more negatively if the guarantors are forced to take a large share. For Oncopeptides, the market will likely focus on the company's cash runway after the issue, the development in sales, and whether the capital raise is deemed sufficient for a longer period or just a temporary solution before further financing is needed. "In connection with the Rights Issue, the Company has entered into a lock-up undertaking, with customary exceptions, according to which the Company's board of directors may not propose or resolve on any new issue during a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided however that the Company has the right to issue and transfer warrants to the European Investment Bank (EIB) (in accordance with the agreement previously entered into between the Company and the EIB). Furthermore, the board members and senior executives of Oncopeptides have undertaken not to sell any shares in Oncopeptides during a period of 180 calendar days after the announcement of the result of the Rights Issue, subject to customary exceptions." In many similar biotech cases, one therefore sees a relatively weak or sluggish share price development during and after the issue period, where the share sometimes reaches a bottom after the subscription period. Thereafter, the share price can either recover in a relief rally when uncertainty decreases, or continue downwards if the market believes that the company will need to raise more capital later on. Next week?
·1 päivä sittenGuarantors are paid for the guaranteed amount regardless of how many shares they ultimately subscribe for. If there are fewer shares than what one has guaranteed, the compensation per share becomes larger.·1 päivä sitten · Muokattu😂 Totally wrong of you
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
79 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenHealthCap - tactical capital strategy Investor Analysis: HealthCap VI and shareholder behavior in Oncopeptides Oncopeptides is in a transition phase where the company is still financed as a development/turnaround case, but at the same time has a commercial product that is starting to generate more structural cash flow expectations. In this situation, the actions of the main shareholders in the 2026 issue become particularly important, especially HealthCap VI and HealthCap VIII. ⸻ 1. HealthCap VI: limited visible issue participation Public information shows that: * HealthCap VIII had clear subscription commitments in the issue. * HealthCap VI is not mentioned as an active issue-supporting party. If HealthCap VI had participated fully pro rata, they could have increased their holding by approximately 7.7 million shares, which would have raised their position to just over 23 million shares. This is not visible in available information. This leads to possible interpretations: Possible scenarios * They completely refrained from subscribing. * They chose not to use the issue as a tool and instead potentially buy shares on the market later. ⸻ 2. Possible tactical capital strategy In small and medium-sized biotech companies, it is not uncommon for larger shareholders to: 1. Participate limitedly in issues when the price is not perceived as optimal. 2. Await important catalysts (e.g., Q1/Q2 reports). 3. Increase exposure in the secondary market if developments confirm the case. This can provide several advantages: * better entry price than the issue price, * greater flexibility in positioning, * opportunity to act after new information rather than before. Since the liquidity in the stock is relatively low, even moderate purchases from institutions can have a significant price impact. ⸻ 3. The flagging pattern: active but selective ownership This is important because it signals that: * the ownership base is still active, * and that the stock is used in more dynamic positioning strategies (not passive long-term ownership). Typical drivers behind such flagging patterns are: * arbitrage linked to issues, * positioning before reports, * market making and liquidity management, * or gradual re-accumulation after capital events. ⸻ 4. Why this is logical in Oncopeptides The company is in an unusual hybrid situation: Operationally: * Product exists and is commercialized. * Sales are growing but are not yet fully stable. Financially: * Cash flow is still negative. * The capital market remains central for financing. Market-wise: * Expectations are divided: between turnaround and continued risk financing. This means that larger shareholders can choose to: * not overexpose themselves in issues, * but instead await commercial confirmation before increasing their stake. ⸻ 5. What the market still discounts That the stock trades below the issue price indicates that the market is still concerned about: * sustainable sales growth, * cash flow profile and burn rate, * potential future capital needs, * and commercial scalability. In practice, the company is still valued more as: a financing case than a stable specialty pharma company. ⸻ 6. Overall interpretation of shareholder behavior HealthCap VI's position can be interpreted in two ways: A. Cautious/neutral interpretation * Capital discipline. * Waiting for a better risk/return profile. * Selective participation in issues. B. Tactical/bullish interpretation * Awaits Q1/Q2 to reduce uncertainty. * Buys later on the market at a weak price. * Optimizes average price rather than locking up capital in an issue. The flagging pattern supports that: * the owners are not abandoning the case, * but rather repositioning themselves. ⸻ 7. Important future signals Bullish signals: 🔥 * increasing net ownership from institutions after reports, * improved sales trend, * reduced cash burn, * partnerships (e.g., Japan), * reduced reliance on issues. Bearish signals: 💀 * continued weak price despite operational improvement, * further capital raising within 12–18 months, * lack of growth acceleration, * decreased institutional interest.·4 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·9 t sittenInvestor Analysis: Oncopeptides – from 6 billion in financing to a market capitalization of 500 Mkr Executive summary Oncopeptides is a clear example of the biotech sector's extreme asymmetry. The company has historically raised approximately: * ~6 billion SEK in capital, but is valued today at approximately: * ~0.5 billion SEK. This means that the market has practically re-evaluated: * the probability of commercial success, * the pipeline value, * and the future cash flow potential very sharply downwards. At the same time, the annual report and regulatory development show that the company is not only trying to commercialize: Pepaxti, but also restructuring its intellectual assets through: Oncopeptides Innovation AB and building further on the PDC platform, including within glioblastoma. This makes the investment case unusually binary: the market today primarily prices in survival and financing risk, while the optionality in the platform largely appears to be discounted away.·4 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·11 t sittenSummary analysis of Oncopeptides Innovation AB and the capital contribution 1. What actually happened In the parent company's note for shares in subsidiaries, a significant increase is visible: * Book value ("carrying amount") for Oncopeptides Innovation AB: * from approximately 25 tkr * to approximately 10,325 tkr * At the same time, it is reported: * Purchases: 10,300 tkr In practice, this means that the parent company has made a capital contribution of approximately 10.3 MSEK to the subsidiary. It is not a matter of: * sales, * operating profit, * or value increase from operations, but an internal financial investment within the group. ⸻ 2. What "Purchases" means here In this type of note, "Purchases" normally means: * shareholder contribution, * new share issue in subsidiary, * or other capitalization. So, it is not about the purchase of goods or operating expenses. The flow is typically: 1. The parent company sends capital to the subsidiary 2. The subsidiary receives: * more cash * higher equity 3. The parent company increases the item: * "shares in subsidiaries" That is why the carrying amount increases so sharply. ⸻ 3. Why Oncopeptides Innovation AB is central Several factors make Oncopeptides Innovation AB appear as the clear recipient: * Started relatively recently * Had very low initial share capital (~25 tkr) * Has: * no employees, * no normal sales, * limited operational activity * At the same time, the company receives a large capital contribution This is a classic pattern for an: * R&D company, * IP company, * or strategic project company within biotech. ⸻ 4. Strategic interpretation The capital contribution does not appear to be administrative or random. It likely signals that Oncopeptides uses Innovation AB as: Möjliga syften (Possible purposes) A. Separate new pipeline or IP Common in biotech: * patents, * preclinical projects, * new technologies are placed in separate companies. Advantages: * risk isolation, * easier partnering, * easier sale, * separate valuation. ⸻ B. Prepare for future license or M&A deals A separate project company makes it easier to: * sell a project, * bring in external investors, * or make collaboration agreements. This is often how larger pharmaceutical companies acquire early technology: * not the entire parent company, * but specific projects or subsidiaries. ⸻ C. Build the next generation pipeline Oncopeptides already has a commercial product: * Pepaxti But the market also knows that the company needs: * new projects, * new pipeline, * future growth. Innovation AB therefore appears to function as: a "container" for future research and development projects. ⸻ 5. Link to pipeline and future projects The analysis points specifically to early projects within: * PDC technology, * new cancer indications, * or preclinical research. A likely example is: * glioblastoma-/GLIOPEP-related projects, * or other early research platforms. The amount (~10 MSEK) is well suited for: * early research, * proof-of-concept, * preclinical development. However, it is too small for larger clinical programs. ⸻ 6. Investor perspective – what the market might miss The most interesting thing is not the sum itself, but the structure. The market tends to focus on: * sales, * quarterly results, * cash flow. But in biotech, the greatest future value is often created: * long before revenues exist. This functions as an option 10.3 MSEK should therefore not primarily be seen as: * a cost, but as: * an investment in future optionality. The outcome is asymmetrical: * the project can become worthless, * or develop into a significant license or acquisition deal. ⸻ 7. Overall assessment Positive signals * The company invests in future pipeline * The structure is strategically well-thought-out * Capital allocation is relatively limited and controlled * Enables future partnering/M&A Risks * No clinical evidence yet * No revenues from the project * Early research phase implies high uncertainty * Future capital needs can lead to dilution ⸻ Conclusion The capital contribution to Oncopeptides Innovation AB is likely a conscious strategic step to build or separate future research projects within the group. It is therefore not just about accounting, but about: * structuring of pipeline, * creation of future business units, * and potential long-term optionality. From an investor's point of view, this is: * potentially an important signal about how Oncopeptides is trying to create the next phase of the company's value development.·3 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·1 päivä sittenOBV trend 📈 The On-Balance Volume (OBV) indicator typically moves in sync with a stock's price, reflecting the balance between buying and selling pressure. This divergence suggests that the recent price weakness has not been driven by higher selling volumes. OBV often acts as an early indicator when investors begin to accumulate long-term positions well before a revaluation.
- ·2 päivää sittenThe situation and going forward In biotech companies, it is often observed that the share price continues to trade weakly during the subscription period itself, especially when the issue is made with such a large discount as in this case, approximately 34 percent against TERP. One reason is that guarantee consortia and arbitrage trading can create additional selling pressure in the share. At the same time, the market usually interprets the situation as the company having now secured its financing, but that it needed to offer very attractive terms to successfully raise the capital. A discount of 34 % is quite aggressive but not uncommon in smaller biotech companies with high risk. This usually signals that the company has prioritized securing capital quickly over protecting the share price level. How the share develops after the issue is often determined by several factors. Investors look closely at how much has been subscribed by existing owners compared to guarantors, and how long the new capital is expected to last. When larger owners and management participate heavily in the issue, it is usually seen as a sign of strength, while it is often perceived more negatively if the guarantors are forced to take a large share. For Oncopeptides, the market will likely focus on the company's cash runway after the issue, the development in sales, and whether the capital raise is deemed sufficient for a longer period or just a temporary solution before further financing is needed. "In connection with the Rights Issue, the Company has entered into a lock-up undertaking, with customary exceptions, according to which the Company's board of directors may not propose or resolve on any new issue during a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided however that the Company has the right to issue and transfer warrants to the European Investment Bank (EIB) (in accordance with the agreement previously entered into between the Company and the EIB). Furthermore, the board members and senior executives of Oncopeptides have undertaken not to sell any shares in Oncopeptides during a period of 180 calendar days after the announcement of the result of the Rights Issue, subject to customary exceptions." In many similar biotech cases, one therefore sees a relatively weak or sluggish share price development during and after the issue period, where the share sometimes reaches a bottom after the subscription period. Thereafter, the share price can either recover in a relief rally when uncertainty decreases, or continue downwards if the market believes that the company will need to raise more capital later on. Next week?·1 päivä sittenGuarantors are paid for the guaranteed amount regardless of how many shares they ultimately subscribe for. If there are fewer shares than what one has guaranteed, the compensation per share becomes larger.·1 päivä sitten · Muokattu😂 Totally wrong of you
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 032 | - | - | ||
| 4 147 | - | - | ||
| 2 402 | - | - | ||
| 7 457 | - | - | ||
| 6 533 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
79 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenHealthCap - tactical capital strategy Investor Analysis: HealthCap VI and shareholder behavior in Oncopeptides Oncopeptides is in a transition phase where the company is still financed as a development/turnaround case, but at the same time has a commercial product that is starting to generate more structural cash flow expectations. In this situation, the actions of the main shareholders in the 2026 issue become particularly important, especially HealthCap VI and HealthCap VIII. ⸻ 1. HealthCap VI: limited visible issue participation Public information shows that: * HealthCap VIII had clear subscription commitments in the issue. * HealthCap VI is not mentioned as an active issue-supporting party. If HealthCap VI had participated fully pro rata, they could have increased their holding by approximately 7.7 million shares, which would have raised their position to just over 23 million shares. This is not visible in available information. This leads to possible interpretations: Possible scenarios * They completely refrained from subscribing. * They chose not to use the issue as a tool and instead potentially buy shares on the market later. ⸻ 2. Possible tactical capital strategy In small and medium-sized biotech companies, it is not uncommon for larger shareholders to: 1. Participate limitedly in issues when the price is not perceived as optimal. 2. Await important catalysts (e.g., Q1/Q2 reports). 3. Increase exposure in the secondary market if developments confirm the case. This can provide several advantages: * better entry price than the issue price, * greater flexibility in positioning, * opportunity to act after new information rather than before. Since the liquidity in the stock is relatively low, even moderate purchases from institutions can have a significant price impact. ⸻ 3. The flagging pattern: active but selective ownership This is important because it signals that: * the ownership base is still active, * and that the stock is used in more dynamic positioning strategies (not passive long-term ownership). Typical drivers behind such flagging patterns are: * arbitrage linked to issues, * positioning before reports, * market making and liquidity management, * or gradual re-accumulation after capital events. ⸻ 4. Why this is logical in Oncopeptides The company is in an unusual hybrid situation: Operationally: * Product exists and is commercialized. * Sales are growing but are not yet fully stable. Financially: * Cash flow is still negative. * The capital market remains central for financing. Market-wise: * Expectations are divided: between turnaround and continued risk financing. This means that larger shareholders can choose to: * not overexpose themselves in issues, * but instead await commercial confirmation before increasing their stake. ⸻ 5. What the market still discounts That the stock trades below the issue price indicates that the market is still concerned about: * sustainable sales growth, * cash flow profile and burn rate, * potential future capital needs, * and commercial scalability. In practice, the company is still valued more as: a financing case than a stable specialty pharma company. ⸻ 6. Overall interpretation of shareholder behavior HealthCap VI's position can be interpreted in two ways: A. Cautious/neutral interpretation * Capital discipline. * Waiting for a better risk/return profile. * Selective participation in issues. B. Tactical/bullish interpretation * Awaits Q1/Q2 to reduce uncertainty. * Buys later on the market at a weak price. * Optimizes average price rather than locking up capital in an issue. The flagging pattern supports that: * the owners are not abandoning the case, * but rather repositioning themselves. ⸻ 7. Important future signals Bullish signals: 🔥 * increasing net ownership from institutions after reports, * improved sales trend, * reduced cash burn, * partnerships (e.g., Japan), * reduced reliance on issues. Bearish signals: 💀 * continued weak price despite operational improvement, * further capital raising within 12–18 months, * lack of growth acceleration, * decreased institutional interest.·4 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·9 t sittenInvestor Analysis: Oncopeptides – from 6 billion in financing to a market capitalization of 500 Mkr Executive summary Oncopeptides is a clear example of the biotech sector's extreme asymmetry. The company has historically raised approximately: * ~6 billion SEK in capital, but is valued today at approximately: * ~0.5 billion SEK. This means that the market has practically re-evaluated: * the probability of commercial success, * the pipeline value, * and the future cash flow potential very sharply downwards. At the same time, the annual report and regulatory development show that the company is not only trying to commercialize: Pepaxti, but also restructuring its intellectual assets through: Oncopeptides Innovation AB and building further on the PDC platform, including within glioblastoma. This makes the investment case unusually binary: the market today primarily prices in survival and financing risk, while the optionality in the platform largely appears to be discounted away.·4 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·11 t sittenSummary analysis of Oncopeptides Innovation AB and the capital contribution 1. What actually happened In the parent company's note for shares in subsidiaries, a significant increase is visible: * Book value ("carrying amount") for Oncopeptides Innovation AB: * from approximately 25 tkr * to approximately 10,325 tkr * At the same time, it is reported: * Purchases: 10,300 tkr In practice, this means that the parent company has made a capital contribution of approximately 10.3 MSEK to the subsidiary. It is not a matter of: * sales, * operating profit, * or value increase from operations, but an internal financial investment within the group. ⸻ 2. What "Purchases" means here In this type of note, "Purchases" normally means: * shareholder contribution, * new share issue in subsidiary, * or other capitalization. So, it is not about the purchase of goods or operating expenses. The flow is typically: 1. The parent company sends capital to the subsidiary 2. The subsidiary receives: * more cash * higher equity 3. The parent company increases the item: * "shares in subsidiaries" That is why the carrying amount increases so sharply. ⸻ 3. Why Oncopeptides Innovation AB is central Several factors make Oncopeptides Innovation AB appear as the clear recipient: * Started relatively recently * Had very low initial share capital (~25 tkr) * Has: * no employees, * no normal sales, * limited operational activity * At the same time, the company receives a large capital contribution This is a classic pattern for an: * R&D company, * IP company, * or strategic project company within biotech. ⸻ 4. Strategic interpretation The capital contribution does not appear to be administrative or random. It likely signals that Oncopeptides uses Innovation AB as: Möjliga syften (Possible purposes) A. Separate new pipeline or IP Common in biotech: * patents, * preclinical projects, * new technologies are placed in separate companies. Advantages: * risk isolation, * easier partnering, * easier sale, * separate valuation. ⸻ B. Prepare for future license or M&A deals A separate project company makes it easier to: * sell a project, * bring in external investors, * or make collaboration agreements. This is often how larger pharmaceutical companies acquire early technology: * not the entire parent company, * but specific projects or subsidiaries. ⸻ C. Build the next generation pipeline Oncopeptides already has a commercial product: * Pepaxti But the market also knows that the company needs: * new projects, * new pipeline, * future growth. Innovation AB therefore appears to function as: a "container" for future research and development projects. ⸻ 5. Link to pipeline and future projects The analysis points specifically to early projects within: * PDC technology, * new cancer indications, * or preclinical research. A likely example is: * glioblastoma-/GLIOPEP-related projects, * or other early research platforms. The amount (~10 MSEK) is well suited for: * early research, * proof-of-concept, * preclinical development. However, it is too small for larger clinical programs. ⸻ 6. Investor perspective – what the market might miss The most interesting thing is not the sum itself, but the structure. The market tends to focus on: * sales, * quarterly results, * cash flow. But in biotech, the greatest future value is often created: * long before revenues exist. This functions as an option 10.3 MSEK should therefore not primarily be seen as: * a cost, but as: * an investment in future optionality. The outcome is asymmetrical: * the project can become worthless, * or develop into a significant license or acquisition deal. ⸻ 7. Overall assessment Positive signals * The company invests in future pipeline * The structure is strategically well-thought-out * Capital allocation is relatively limited and controlled * Enables future partnering/M&A Risks * No clinical evidence yet * No revenues from the project * Early research phase implies high uncertainty * Future capital needs can lead to dilution ⸻ Conclusion The capital contribution to Oncopeptides Innovation AB is likely a conscious strategic step to build or separate future research projects within the group. It is therefore not just about accounting, but about: * structuring of pipeline, * creation of future business units, * and potential long-term optionality. From an investor's point of view, this is: * potentially an important signal about how Oncopeptides is trying to create the next phase of the company's value development.·3 min sittenAI has helped with the formulation of the text, but the content is based on my own thoughts and analysis. It has primarily been used to develop and clarify what I myself have identified.
- ·1 päivä sittenOBV trend 📈 The On-Balance Volume (OBV) indicator typically moves in sync with a stock's price, reflecting the balance between buying and selling pressure. This divergence suggests that the recent price weakness has not been driven by higher selling volumes. OBV often acts as an early indicator when investors begin to accumulate long-term positions well before a revaluation.
- ·2 päivää sittenThe situation and going forward In biotech companies, it is often observed that the share price continues to trade weakly during the subscription period itself, especially when the issue is made with such a large discount as in this case, approximately 34 percent against TERP. One reason is that guarantee consortia and arbitrage trading can create additional selling pressure in the share. At the same time, the market usually interprets the situation as the company having now secured its financing, but that it needed to offer very attractive terms to successfully raise the capital. A discount of 34 % is quite aggressive but not uncommon in smaller biotech companies with high risk. This usually signals that the company has prioritized securing capital quickly over protecting the share price level. How the share develops after the issue is often determined by several factors. Investors look closely at how much has been subscribed by existing owners compared to guarantors, and how long the new capital is expected to last. When larger owners and management participate heavily in the issue, it is usually seen as a sign of strength, while it is often perceived more negatively if the guarantors are forced to take a large share. For Oncopeptides, the market will likely focus on the company's cash runway after the issue, the development in sales, and whether the capital raise is deemed sufficient for a longer period or just a temporary solution before further financing is needed. "In connection with the Rights Issue, the Company has entered into a lock-up undertaking, with customary exceptions, according to which the Company's board of directors may not propose or resolve on any new issue during a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided however that the Company has the right to issue and transfer warrants to the European Investment Bank (EIB) (in accordance with the agreement previously entered into between the Company and the EIB). Furthermore, the board members and senior executives of Oncopeptides have undertaken not to sell any shares in Oncopeptides during a period of 180 calendar days after the announcement of the result of the Rights Issue, subject to customary exceptions." In many similar biotech cases, one therefore sees a relatively weak or sluggish share price development during and after the issue period, where the share sometimes reaches a bottom after the subscription period. Thereafter, the share price can either recover in a relief rally when uncertainty decreases, or continue downwards if the market believes that the company will need to raise more capital later on. Next week?·1 päivä sittenGuarantors are paid for the guaranteed amount regardless of how many shares they ultimately subscribe for. If there are fewer shares than what one has guaranteed, the compensation per share becomes larger.·1 päivä sitten · Muokattu😂 Totally wrong of you
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 032 | - | - | ||
| 4 147 | - | - | ||
| 2 402 | - | - | ||
| 7 457 | - | - | ||
| 6 533 | - | - |
Välittäjätilasto
Dataa ei löytynyt